vs

Side-by-side financial comparison of Ginkgo Bioworks Holdings, Inc. (DNA) and Mediaco Holding Inc. (MDIA). Click either name above to swap in a different company.

Mediaco Holding Inc. is the larger business by last-quarter revenue ($38.7M vs $33.4M, roughly 1.2× Ginkgo Bioworks Holdings, Inc.). On growth, Mediaco Holding Inc. posted the faster year-over-year revenue change (17.9% vs -23.8%). Mediaco Holding Inc. produced more free cash flow last quarter ($-460.0K vs $-47.7M). Over the past eight quarters, Mediaco Holding Inc.'s revenue compounded faster (140.1% CAGR vs -6.2%).

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

MediaCo Holding Inc. is an American media company with offices based in Burbank, California and New York City, owned by private equity firms HPS Investment Partners, LLC and Standard General. MediaCo caters to the African-American and the Spanish-speaking Hispanic communities. The company owns television and radio stations in several of the top multicultural markets, and is the parent company of the Estrella TV network.

DNA vs MDIA — Head-to-Head

Bigger by revenue
MDIA
MDIA
1.2× larger
MDIA
$38.7M
$33.4M
DNA
Growing faster (revenue YoY)
MDIA
MDIA
+41.7% gap
MDIA
17.9%
-23.8%
DNA
More free cash flow
MDIA
MDIA
$47.2M more FCF
MDIA
$-460.0K
$-47.7M
DNA
Faster 2-yr revenue CAGR
MDIA
MDIA
Annualised
MDIA
140.1%
-6.2%
DNA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DNA
DNA
MDIA
MDIA
Revenue
$33.4M
$38.7M
Net Profit
$-32.3M
Gross Margin
Operating Margin
-211.9%
-16.0%
Net Margin
-83.6%
Revenue YoY
-23.8%
17.9%
Net Profit YoY
-661.9%
EPS (diluted)
$-1.41
$-0.39

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DNA
DNA
MDIA
MDIA
Q4 25
$33.4M
$38.7M
Q3 25
$38.8M
$35.4M
Q2 25
$49.6M
$31.2M
Q1 25
$48.3M
$28.0M
Q4 24
$43.8M
$32.8M
Q3 24
$89.0M
$29.9M
Q2 24
$56.2M
$26.2M
Q1 24
$37.9M
$6.7M
Net Profit
DNA
DNA
MDIA
MDIA
Q4 25
$-32.3M
Q3 25
$-80.8M
$-17.9M
Q2 25
$-60.3M
$-7.4M
Q1 25
$-91.0M
$-8.6M
Q4 24
$-4.2M
Q3 24
$-56.4M
$54.9M
Q2 24
$-217.2M
$-48.3M
Q1 24
$-165.9M
$-3.7M
Operating Margin
DNA
DNA
MDIA
MDIA
Q4 25
-211.9%
-16.0%
Q3 25
-231.8%
-20.0%
Q2 25
-132.1%
-21.7%
Q1 25
-184.1%
-16.7%
Q4 24
-236.3%
-13.8%
Q3 24
-62.0%
-23.0%
Q2 24
-396.7%
-50.9%
Q1 24
-469.1%
-51.7%
Net Margin
DNA
DNA
MDIA
MDIA
Q4 25
-83.6%
Q3 25
-207.9%
-50.5%
Q2 25
-121.6%
-23.7%
Q1 25
-188.2%
-30.7%
Q4 24
-12.9%
Q3 24
-63.3%
184.0%
Q2 24
-386.4%
-184.4%
Q1 24
-437.3%
-54.8%
EPS (diluted)
DNA
DNA
MDIA
MDIA
Q4 25
$-1.41
$-0.39
Q3 25
$-1.45
$-0.22
Q2 25
$-1.10
$-0.11
Q1 25
$-1.68
$-0.12
Q4 24
$-1.91
$0.19
Q3 24
$-1.08
$0.66
Q2 24
$-4.23
$-0.75
Q1 24
$-3.32
$-0.18

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DNA
DNA
MDIA
MDIA
Cash + ST InvestmentsLiquidity on hand
$422.6M
$5.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$508.6M
$46.3M
Total Assets
$1.1B
$291.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DNA
DNA
MDIA
MDIA
Q4 25
$422.6M
$5.1M
Q3 25
$495.5M
$6.2M
Q2 25
$559.4M
$2.9M
Q1 25
$325.3M
$6.3M
Q4 24
$561.6M
$4.4M
Q3 24
$616.2M
$7.7M
Q2 24
$730.4M
$9.9M
Q1 24
$840.4M
$4.0M
Stockholders' Equity
DNA
DNA
MDIA
MDIA
Q4 25
$508.6M
$46.3M
Q3 25
$559.8M
$86.7M
Q2 25
$613.0M
$97.3M
Q1 25
$647.4M
$85.5M
Q4 24
$716.1M
$62.1M
Q3 24
$797.9M
$67.9M
Q2 24
$833.1M
$13.7M
Q1 24
$987.3M
$33.3M
Total Assets
DNA
DNA
MDIA
MDIA
Q4 25
$1.1B
$291.1M
Q3 25
$1.2B
$319.4M
Q2 25
$1.2B
$315.1M
Q1 25
$1.3B
$317.7M
Q4 24
$1.4B
$325.5M
Q3 24
$1.5B
$338.4M
Q2 24
$1.6B
$338.6M
Q1 24
$1.6B
$325.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DNA
DNA
MDIA
MDIA
Operating Cash FlowLast quarter
$-47.7M
$32.0K
Free Cash FlowOCF − Capex
$-47.7M
$-460.0K
FCF MarginFCF / Revenue
-142.8%
-1.2%
Capex IntensityCapex / Revenue
0.0%
1.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DNA
DNA
MDIA
MDIA
Q4 25
$-47.7M
$32.0K
Q3 25
$-31.6M
$2.8M
Q2 25
$-40.3M
$-3.0M
Q1 25
$-51.5M
$2.1M
Q4 24
$-42.4M
$10.9M
Q3 24
$-103.5M
$-6.0M
Q2 24
$-84.4M
$-25.1M
Q1 24
$-89.3M
$412.0K
Free Cash Flow
DNA
DNA
MDIA
MDIA
Q4 25
$-47.7M
$-460.0K
Q3 25
$2.8M
Q2 25
$-40.3M
$-3.2M
Q1 25
$-59.1M
$2.0M
Q4 24
$-56.1M
$10.5M
Q3 24
$-118.6M
$-6.6M
Q2 24
$-111.4M
$-25.2M
Q1 24
$-96.0M
$386.0K
FCF Margin
DNA
DNA
MDIA
MDIA
Q4 25
-142.8%
-1.2%
Q3 25
8.0%
Q2 25
-81.2%
-10.2%
Q1 25
-122.4%
7.1%
Q4 24
-128.0%
31.9%
Q3 24
-133.2%
-22.2%
Q2 24
-198.2%
-96.1%
Q1 24
-252.9%
5.8%
Capex Intensity
DNA
DNA
MDIA
MDIA
Q4 25
0.0%
1.3%
Q3 25
0.0%
0.0%
Q2 25
0.1%
0.7%
Q1 25
15.8%
0.2%
Q4 24
31.3%
1.2%
Q3 24
16.9%
2.1%
Q2 24
48.1%
0.3%
Q1 24
17.7%
0.4%
Cash Conversion
DNA
DNA
MDIA
MDIA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
-0.11×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

MDIA
MDIA

Video Segment$26.4M68%
Advertising$10.0M26%
Other$1.7M4%
Service Other$536.0K1%

Related Comparisons